Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FeRX tests MTC (Magnetic Targeted Carrier)-based gene therapy in Japan:

This article was originally published in Clinica

Executive Summary

FeRx has entered into a research agreement with Japan's National Cancer Center Research Institute (NCCRI) to develop a tumour-targeting gene transfer approach that uses FeRx's Magnetic Targeted Carrier (MTC) drug delivery technology. "An important goal of the collaboration will be improvement of the site specific delivery of genetic vectors to the disease site, one of the continuing development challenges facing gene therapy," said Dr Takahiro Ochiya of the NCCRI. MTC uses magnetic fields to target agents to specific areas in the body. The San Diego, California firm is already testing the method in the treatment of cancers (see Clinica No 1010, p 24).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel